{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:45:03Z","timestamp":1792125903708,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:20:43Z","timestamp":1790068843000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative enfortumab vedotin\u2013pembrolizumab, gemcitabine-cisplatin\u2013durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-8174","authenticated-orcid":false,"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-8845","authenticated-orcid":false,"given":"Daniel A.","family":"Gonz\u00e1lez-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-0191","authenticated-orcid":false,"given":"Aleksander","family":"Slusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-3465","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-0344","authenticated-orcid":false,"given":"Alberto","family":"Artiles-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-8602","authenticated-orcid":false,"given":"Jorge","family":"Ca\u00f1o-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0596","authenticated-orcid":false,"given":"J\u00falia","family":"Aumatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-2342","authenticated-orcid":false,"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-5553","authenticated-orcid":false,"given":"Francesco","family":"Claps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5156-7080","authenticated-orcid":false,"given":"Pablo","family":"Gajate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2904-3699","authenticated-orcid":false,"given":"Patricia","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-6945","authenticated-orcid":false,"given":"Felipe","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-6209","authenticated-orcid":false,"given":"Eduardo Albers","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-1532","authenticated-orcid":false,"given":"Albert","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-1448","authenticated-orcid":false,"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-8351","authenticated-orcid":false,"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0705-7643","authenticated-orcid":false,"given":"Mario","family":"Alvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"San-Jos\u00e9 Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gomez Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Burgos Revilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-8558","authenticated-orcid":false,"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Buisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.urolonc.2026.09.007_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.urolonc.2026.09.007_bib0002","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.007_bib0003","first-page":"49","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU VESPER phase 3 randomized trial","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.09.007_bib0004","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"Van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2026.09.007_bib0005","first-page":"1959","article-title":"Neoadjuvant durvalumab plus gemcitabine-cisplatin for muscle-invasive bladder cancer (NIAGARA): a randomised, open-label, phase 3 trial","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0006","unstructured":"U.S. Food and Drug Administration. FDA approves durvalumab for muscle invasive bladder cancer. March 28, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-muscle-invasive-bladder-cancer. Accessed October 8, 2026"},{"issue":"4","key":"10.1016\/j.urolonc.2026.09.007_bib0007","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.09.007_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.09.007_bib0023","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2025.07.021","article-title":"Guidelines for meta-analyses and systematic reviews in urology","volume":"88","author":"Vickers","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.urolonc.2026.09.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.007_bib0016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.007_bib0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.09.007_bib0011","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.09.007_bib0009","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.007_bib0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.09.007_bib0018","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.09.007_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0020","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer. July 10, 2026.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin. Accessed October 8, 2026."},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.007_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1590\/s1677-5538.ibju.2022.0405","article-title":"Perioperative mortality for radical cystectomy in the modern era: experience from a tertiary referral center","volume":"49","author":"Sobhani","year":"2023","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.01.003","article-title":"Prognostic factors for overall survival in the VESPER trial: basal molecular subtype is a relevant key factor","author":"Pfister","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.09.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.09.007_bib0025","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","article-title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab in NIAGARA","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:55:34Z","timestamp":1792122934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S1078143926007386"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative enfortumab vedotin\u2013pembrolizumab, gemcitabine-cisplatin\u2013durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}